ValiRx PLC New Evaluation Agreement (9162L)
16 Septiembre 2021 - 12:59AM
UK Regulatory
TIDMVAL
RNS Number : 9162L
ValiRx PLC
16 September 2021
16 September 2021
ValiRx PLC ("ValiRx" or the "Company")
Commences new Evaluation Agreement
ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, has entered an
Evaluation Agreement with a leading London university to
investigate a novel technology designed to treat breast cancer.
Under the agreement, the Company will carry out a defined series
of preclinical tests on the drug candidate molecule over the next
nine months to validate the technology and determine suitability
for commercialisation. This preclinical evaluation, the cost of
which will be borne by ValiRx up to GBP75,000, will investigate the
action of the molecule against Triple Negative Breast Cancer and
other indications.
At the conclusion of the evaluation period the Company has an
option to license the technology on pre-agreed terms.
Dr Suzy Dilly, CEO of ValiRx commented "I'm delighted to have
secured our next evaluation programme, which, if successful, will
achieve the dual objective of building a pipeline in both women's
health and oncology. We are also delighted that the Principal
Investigator of this exciting technology is keen to remain actively
involved in the next stages of development."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 as it forms part of
UK Domestic Law by virtue of the European Union (Withdrawal) Act
2018 ("UK MAR").
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476 796496
Dr Suzanne Dilly, CEO www.valirx.com
Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP Tel: +44 (0) 20 7213 088
(Nominated Adviser)
Liam Murray/Jo Turner/Ludovico
Lazzaretti
--------------------------
Cenkos Securities Limited (Broker) Tel: +44 (0) 20 7397 8900
Russell Kerr/Michael Johnson
(Sales)
Callum Davidson/Giles Balleny
(Corporate Finance)
--------------------------
Notes for Editors
About ValiRx
ValiRx accelerates the development of treatments in oncology and
women's health to improve patient lives. We provide the scientific,
financial and commercial framework towards enabling rapid
translation of innovative science into clinical development.
With our extensive and proven experience in research and drug
development, we select and incubate promising novel drug candidates
and guide them through an optimised process of development, from
pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and
commercial domains, with the aim of achieving a more streamlined,
less costly, drug development process. We work closely with our
selected collaborators and leverage the combined expertise required
for science to advance.
Lead candidates from our portfolio are out-licensed or partnered
with investors through ValiRx subsidiary
companies for further clinical development and commercialisation. https://www.valirx.com/
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
About Breast Cancer
Breast Cancer is any cancer that originates in breast tissue.
Over 50,000 cases of Breast Cancer are identified in the UK every
year, with over 99% of these in women.
Breast Cancer is identified by type, with the biochemical
characteristics of the cancerous cells allowing doctors to assess
the best course of treatment for the patient. Cells can display
receptors that allow them to respond to hormones such as Estrogen,
Progesterone and the HER2 protein. These receptors provide a target
for treatments to work against the cancer. In triple negative
breast cancer which accounts for around 15% of breast cancers,
these receptors are not present on the cell, so treatment options
are more limited, and prognosis poorer.
Cautionary statement
Certain statements made in this announcement are forward-looking
statements. Such statements are based on current expectations and
assumptions and are subject to a number of risks and uncertainties
that could cause actual events or results to differ materially from
any expected future events or results expressed or implied in these
forward-looking statements. Persons receiving this announcement
should not place undue reliance on forward-looking statements.
Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or
revise any forward-looking statements, whether as a result of new
information, future developments or otherwise.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRFLFIRADIELIL
(END) Dow Jones Newswires
September 16, 2021 01:59 ET (05:59 GMT)
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024